Consumer Health, Seventh Edition
References for Chapter 15
Cardiovascular Disease

  1. American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas, 1999, The Association. [Update, 2001]
  2. American Heart Association. Silent epidemic: The truth about women and heart disease. Dallas, 1989, The Association.
  3. Steenland K. Passive smoking and the risk of heart disease. JAMA 267:94-99, 1992.
  4. Willett WC and others. Coffee consumption and coronary heart disease in women: A ten-year follow-up. JAMA 275:458-462, 1996.
  5. Triglycerides and heart disease. Harvard Heart Letter 11(1):1-5, 2000.
  6. Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA 263:1795-1801, 1990.
  7. Castelli WP and others. Incidence of coronary heart disease and lipoprotein cholesterol levels-the Framingham Study. JAMA 256:2835-2838, 1986.
  8. Anderson KM and others. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 257:2176-2180, 1987.
  9. Samuelson O and others. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. JAMA 258:1768-1776, 1987.
  10. Gotto AM Jr and others. The cholesterol facts -- a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Dallas, 1990, American Heart Association.
  11. Lipid Clinics Research Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary artery disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:351-374, 1984.
  12. Rader DJ, Brewer HB. Lipoprotein(a): Clinical approach to a unique atherogenic lipoprotein. JAMA 267:1109-1112, 1992.
  13. Schaefer EJ. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 271:999-1003, 1994.
  14. Gurewich V, Mittleman M. Lipoprotein(a) in coronary disease: Is it a risk factor after all? JAMA 271:1025-1026, 1994.
  15. Ridker PM and others. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195-2199, 1993.
  16. Bostom AG and others. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. JAMA 276:544-548, 1996.
  17. Maher VM and others. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274:1771-1774, 1995.
  18. Ridker PM and others. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273:1269-1273, 1995.
  19. Boushey CJ and others. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274:1049-1057, 1995.
  20. Morrison HI and others. Serum folate and risk of fatal coronary heart disease. JAMA 275:1893-1896, 1996.
  21. Stampfer M, Nalinow MR. Can lowering homocysteine levels reduce cardiovascular risk? New England Journal of Medicine 332:328-329, 1995.
  22. Grundy SM and others. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 269:3015-3023, 1993.
  23. Johnson CL and others. Declining serum cholesterol levels among U.S. adults: The National Health and Nutrition Examination Surveys. JAMA 269:3002-3008, 1993.
  24. Sempos CT and others. Prevalence of high blood cholesterol among US adults. JAMA 269:3009-3014, 1993.
  25. National Institutes of Health. Report of the expert panel on blood cholesterol levels in children and adolescents. Bethesda, Md., 1991, The Institutes.
  26. Barnard RJ. Effects of life-style modification on serum lipids. Archives of Internal Medicine 151:1389-1394, 1991.
  27. Mirkin G, Rich D. Fat Free, Flavor Full. Boston, 1995, Little, Brown and Company.
  28. Heinz A. Facts and myths about coronary artery disease: A consumer guide. New York, 1989, American Council on Science and Health.
  29. U.S Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd edition. Baltimore, 1996, Williams & Wilkins.
  30. Garber AM and others. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Annals of Internal Medicine 124:515-517, 1996.
  31. Grundy S and others. Cholesterol screening in adults: No cause to change. Circulation 93:1067-1068, 1996.
  32. LaRosa JC. Cholesterol agonistics. Annals of Internal Medicine 124:505-508, 1996.
  33. A woman's heart. Harvard Heart Letter 17(6):5-7, 1992.
  34. Denke MA, Winker MA. Cholesterol and coronary heart disease in older adults: No easy answers. JAMA 274:575-577, 1995.
  35. Newman B, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60, 1996.
  36. Dalen JE, Dalton WS. Does cholesterol lowering cause cancer? JAMA 275:67-68, 1996.
  37. Cooper GR and others. Blood lipid measurements: Variations and practical utility. JAMA 267:1652-1660, 1992.
  38. What's your cholesterol? You need to understand your cholesterol profile to know what to do about it. Consumer Reports on Health 3:81-83, 1991.
  39. Lichtenstein AH. Trans fatty acids, plasma lipid levels, and risk of developing cardiovascular disease: A statement for health professionals. Circulation 95:2588-2590, 1997.
  40. Food labeling: Trans fatty acids in nutrition labeling, Nutrient content claims, and health claims; Proposed rule. Federal Register 64: 62745-62825, 1999.
  41. Rimm EB and others. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 275:447-451, 1996.
  42. Gillman MW and others. Protective effects of fruits and vegetables on development of stroke in men. JAMA 273:1113-1117, 1995.
  43. Step By Step: Eating to Lower Your High Blood Cholesterol. NIH publication no. 94-2920. Washington, D.C., 1994, Supt. of Documents.
  44. Kraus RM and others. AHA dietary guidelines, revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102:2284-2299, 2000.
  45. Barrett S, Kantor MA. Tips for lowering your dietary fat content. Quackwatch Web site, March 31, 2000.
  46. USDA Food composition data. USDA Nutrient Data Laboratory Web site, accessed Feb 17, 2000.
  47. Kantor MA. Nutrition, cholesterol and heart disease. Part V. Dietary modification. Nutrition Forum 6:33-37, 1989.
  48. Anderson JW and others. Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. American Journal of Clinical Nutrition 40:1146-1155, 1984.
  49. Bell LP and others. Cholesterol-lowering effects of psyllium hydrophilic mucilloid-adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia. JAMA 261:3419-3423, 1989.
  50. Rimm EB and others. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 275:447-451, 1996.
  51. Wolk A and others. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women. JAMA 281:1998-2004, 1999.
  52. Gillman MW and others. Protective effect of fruits and vegetables on development of stroke in men. JAMA 273:1113-1117, 1995.
  53. Joshipura KJ and others. Fruit and vegetable intake in relation to risk of stroke. JAMA 282:1233-1239, 1999.
  54. Ripsin CM. Oat products and lipid lowering: A meta-analysis. JAMA 267:3317-3325, 1992.
  55. Davidson MH and others. The hypocholesterolemic effects of b-glucan in oatmeal and oat bran. JAMA 265:1833-1839, 1991.
  56. Milani RV, Lavie CJ. Pharmacologic prevention of coronary artery disease. What do clinical trials show? Postgraduate Medicine 99:109-120, 1996.
  57. Gotto AM Jr. Lipid lowering, regression, and coronary events: A review of the interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation 92:646-656, 1995.
  58. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994.
  59. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345:1274-1275, 1995.
  60. Byington RP and others. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 92:2419-2925, 1995.
  61. Gould AL and others. Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 91:2274-2282, 1995.
  62. Ornish D and others. Can lifestyle changes reverse coronary heart disease? Lancet 336:129-133, 1990.
  63. Gould KL, Ornish D and others. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. American Journal of Cardiology 69:845-853, 1992.
  64. Gould KL, Ornish D and others. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 274:894-901, 1995.
  65. Ornish D and others. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280:2001-2007, 1998.
  66. Pritikin R. The new Pritikin Program: The easy and delicious way to shed fat, lower your cholesterol, and stay fit. New York, 1990, Simon & Schuster.
  67. New York City Department of Consumer Affairs. Supermarket Survey on Misleading Cholesterol Claims. New York, 1991, The Department.
  68. Choice of lipid-lowering drugs. The Medical Letter 38:117-122, 1998.
  69. Hodes HN. Acute hepatic failure associated with low-dose sustained-release niacin. JAMA 264:181, 1990.
  70. Henkin Y. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA 264:241-243, 1990.
  71. Etchason JA and others. Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin. Mayo Clinic Proceedings 66:23-28, 1991.
  72. McKenney JM and others. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271:672-677, 1994.
  73. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. British Medical Journal 308:81-106, 159-168, 235-246, 1994.
  74. Hennekens CH and others. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare pro-fessionals from the American Heart Association. Circulation 96:2751-2753, 1997.
  75. A vitamin cocktail for cholesterol? Consumer Reports 55:141, 1990.
  76. Goldfinger SE. Good for what ails you? Harvard Health Letter 16(10):1-2, 1991.
  77. Kushi LH and others. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. New England Journal of Medicine 334:1156-1162, 1996.
  78. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. New England Journal of Medicine 342:145-153, 2000.
  79. Hennekens CH and others. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. New England Journal of Medicine 334:1145-1149, 1996.
  80. Knuiman A and others. Lecithin intake and serum cholesterol. American Journal of Clinical Nutrition 49:266-268, 1989.
  81. Coenzyme Q10: the next aspirin? Harvard Heart Letter 6(6):5-7, 1996.
  82. Kwiterovich P. Beyond Cholesterol: The Johns Hopkins Complete Guide for Avoiding Heart Disease. Baltimore, 1989, The Johns Hopkins University Press.
  83. Siscovick DS and others. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 274:1363-1367, 1995.
  84. Ascherio A and others. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. New England Journal of Medicine 332:977-982, 1995.
  85. Southwestern News, University of Texas Southwestern Medical Center, Jan 2, 1997.
  86. Gaziano JM and others. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. New England Journal of Medicine 329:1829-1834, 1993.
  87. Friedman GD, Klatsky AL. Is alcohol good for your health? New England Journal of Medicine 329:1882-1883, 1993.
  88. Cholesterol-lowering margarines. The Medical Letter 41:56-58, 1999.
  89. Reeves RA. Does this patient have hypertension? How to measure blood pressure. JAMA 273:1211-1218, 1995.
  90. Farley D. High blood pressure: Controlling the silent killer. FDA Consumer 25(10):28-33, 1991.
  91. Gifford RW and others. Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md., 1993, National Institutes of Health.
  92. Stamler R and others. Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized, controlled trial. JAMA 262:1801-1807, 1989.
  93. Bucher HC and others. Effects of dietary calcium supplementation on blood pressure: A meta-analysis of randomized controlled trials. JAMA 275:1016-1022, 1996.
  94. American College of Sports Medicine position stand: Physical activity, physical fitness, and hypertension. Medical Science of Sports and Exercise 25(10):i-x, 1993. [Full text can be accessed by following the links to ACSM position stands.]
  95. Weinberger MH and others. Dietary sodium restriction as adjunctive treatment of hypertension. JAMA 259:2561-2565, 1988.
  96. Lowering blood pressure without drugs. Harvard Heart Letter 2(9):1-5, 1992.
  97. How to lower blood pressure. Consumer Reports 57:300-302, 1992.
  98. Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. JAMA 267:1213-1220, 1992.
  99. Appel LJ and others. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. New England Journal of Medicine 336:1117-1124, 1997.
  100. ACE inhibitors for hypertension. Harvard Heart Letter 2(6):5-8, 1992.
  101. Muntzel M, Drëeke T. A comprehensive review of the salt and blood pressure relationship. American Journal of Hypertension 5:1S-42S, 1992.
  102. When the electrocardiogram is abnormal. Harvard Heart Letter 5(3):1-5, 1994.
  103. Lee TH and others. Coronary Artery Disease: Diagnosis and Treatment. Boston, 1994, Harvard Publications Group.
  104. Fletcher GF and others. Exercise standards: A statement for healthcare professionals from the American Heart Association. Circulation 91:580-615, 1995.
  105. Stress tests: Who needs them? Harvard Heart Letter 1(1):1-4, 1990.
  106. What is an exercise stress test? The Johns Hopkins Medical Letter 3(10):6-7, 1991.
  107. Budoff MJ and others. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: A multicenter study. Circulation 93:898-904, 1996.
  108. O'Rourke RA and others. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102:126-140, 2000.
  109. Feigenbaum H and others. Tracking the advances in echocardiography. Patient Care, pp 14-45, Mar 15, 1991.
  110. O'Connor GT and others. A regional prospective study of in-hospital mortality associated with coronary artery bypass grafting. JAMA 266:803-809, 1991.
  111. Coronary artery bypass surgery today, Harvard Heart Letter 2(7):1-7, 1992.
  112. Myers WO and others. CASS Registry long term surgical survival. Coronary Artery Surgery Study. Journal of the American College of Cardiology 33:488-498, 1999.
  113. Bypass surgery. Who really needs it? Consumer Reports on Health 4(7):49-52, 1992.
  114. Farley D. Balloons, lasers and scrapers: Help for hearts and blood vessels. FDA Consumer 25(3):22-27, 1991.
  115. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. JAMA 277:715-721, 1997.
  116. Seven-year outcome in the Bypass Angioplasty Re-vascularization Investigation (BARI) by treatment and diabetic status. Journal of the American College of Cardiology 35:1122-1129, 2000.
  117. Bypass surgery: Making the right choice. The Johns Hopkins Health Letter 3(11):4-5, 1992.
  118. Pfeiffer N. The great cardiology debate: Angioplasty. Medical World News, pp 28-30, Jan 1992.
  119. Zoler ML. Rehabilitation-a boon of the thrombolytic era. Medical World News, pp 35-44, March 13, 1989.
  120. American College of Sports Medicine position stand: Exercise for patients with coronary artery disease. Medical Science of Sports and Exercise 26(3):i-v, 1994. [Full text can be accessed by following the links to ACSM position stands.]

This page was posted on December 22, 2001.

Sponsored Links to Recommended Companies